Spruce Biosciences
6
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
66.7%
4 terminated/withdrawn out of 6 trials
33.3%
-53.2% vs industry average
0%
0 trials in Phase 3/4
300%
6 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Role: lead
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Role: lead
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Role: lead
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Role: lead
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Role: lead
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Role: lead
All 6 trials loaded